or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management of gliomas are ongoing, it cannot be excluded, in case of ...

2024年9月13-17日，2024年欧洲肿瘤内科学会（ESMO）年会于西班牙巴塞罗那正式召开。作为肿瘤领域最具权威的年度盛会之一，本届年会再次云集全球肿瘤大咖、汇聚领域最新进展。

Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on C4 Therapeutics (CCCC – Research Report). The associated price ...

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma ...

Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on C4 Therapeutics (CCCC – Research Report). The associated ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients ...